Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

SAB Biotherapeutics (SABS) Return on Capital Employed (2021 - 2026)

SAB Biotherapeutics filings provide 6 years of Return on Capital Employed readings, the most recent being 28.98% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 10527.0% to 28.98% in Q1 2026 year-over-year; TTM through Mar 2026 was 28.98%, a 10527.0% increase, with the full-year FY2025 number at 50.04%, up 2646.0% from a year prior.
  • Return on Capital Employed hit 28.98% in Q1 2026 for SAB Biotherapeutics, up from 29.23% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 9.15% in Q3 2023 to a low of 178.37% in Q2 2025.
  • Median Return on Capital Employed over the past 5 years was 51.7% (2022), compared with a mean of 62.39%.
  • Biggest five-year swings in Return on Capital Employed: plummeted -10086bps in 2025 and later skyrocketed 10527bps in 2026.
  • SAB Biotherapeutics' Return on Capital Employed stood at 10.71% in 2022, then plummeted by -685bps to 84.0% in 2023, then dropped by -25bps to 104.62% in 2024, then soared by 72bps to 29.23% in 2025, then grew by 1bps to 28.98% in 2026.
  • The last three reported values for Return on Capital Employed were 28.98% (Q1 2026), 29.23% (Q4 2025), and 44.99% (Q3 2025) per Business Quant data.